Foundayo: the GLP-1 pill without the food rules
Foundayo (orforglipron) is the newest weight-management medicine in the UK — a daily tablet that works on GLP-1 receptors without injections and, unlike the Wegovy pill, without fasting-and-waiting routines. Here is what it is, who it suits, and how to get it through regulated providers only.
Independently written · Last reviewed: · editorial policy
Key facts in 30 seconds
- Foundayo (orforglipron) is a daily tablet GLP-1 — a small molecule, not a peptide — with no food-timing rules.
- That distinguishes it from the Wegovy pill (oral semaglutide), which has strict fasting requirements.
- It is available in the UK through regulated providers; the safe route is consultation plus a GPhC-registered pharmacy.
- Regulated providers are listed independently at dayo.co.uk.
- As with every GLP-1: no legitimate seller skips the clinical consultation — verify the pharmacy on the GPhC register.
What Foundayo is
Foundayo is the brand name for orforglipron, a once-daily tablet from Eli Lilly for weight management. It belongs to the GLP-1 medicine class, but with a twist that matters in daily life: orforglipron is a small molecule, not a peptide. Peptide GLP-1s — semaglutide and tirzepatide — are broken down by digestion, which is why they must be injected or, as a tablet, surrounded by strict food-timing rules. A small molecule is absorbed differently, so Foundayo can be taken with or without food, with no 30-minute waiting window and no sharps bin.
It entered the UK market in 2026 as an authorised prescription option, alongside the established injections and the Wegovy pill. Its main obesity trial programme (the ATTAIN studies) reported average weight loss in the region of 11–12% at the highest doses over 72 weeks — a solid result that sits below the strongest injections, as oral medicines in this class generally do, while beating the “no needle, no food rules” convenience test they cannot.
Where it fits: the four-way picture
| Format | Routine | Typical average effect | |
|---|---|---|---|
| Mounjaro (tirzepatide) | Weekly injection | One pen, same day weekly | ≈20.9% (SURMOUNT-1) |
| Wegovy (semaglutide) | Weekly injection | One pen, same day weekly | ≈14.9% (STEP 1) |
| Wegovy pill (oral semaglutide) | Daily tablet | Fasting dose, 30-min wait before food | Somewhat lower than the injection |
| Foundayo (orforglipron) | Daily tablet | With or without food — no timing rules | ≈11–12% (ATTAIN programme) |
Cross-trial numbers are indicative, not head-to-head: different trials, durations and populations. The pattern to hold onto is simpler — injections currently deliver the largest average effect; tablets trade some of that effect for convenience. Foundayo pushes the convenience end furthest among the authorised options.
The only safe way to buy Foundayo in the UK
- Consultation first, always. Foundayo is a prescription-only medicine. A regulated provider assesses eligibility, medical history and interactions before any prescription — the same legal pathway as every medicine on this site.
- Verify the pharmacy on the GPhC register. Search the exact name at pharmacyregulation.org — not the number on the seller's own footer.
- Start from a regulated-provider list. dayo.co.uk maintains a list of regulated UK Foundayo providers, so your shortlist begins with pharmacies verified against the official registers rather than whoever bought the advert.
- Confirm the full monthly cost. A daily tablet is a 30-dose month. Get the complete delivered price — medicine, consultation, prescription and delivery — in writing before paying, and watch for introductory pricing that jumps at renewal.
- Report anything odd. New brands attract counterfeiters fastest. If a product, packet or leaflet looks wrong, do not take it — report via the MHRA Yellow Card scheme.
The newest medicine is the scammers' freshest bait
- “Orforglipron powder”, “research capsules” or compounded tablets — unlicensed, unverifiable, illegal to supply for human use.
- Sites selling Foundayo with no consultation, or before supply is genuinely established — if it is cheaper and easier than every verified provider, ask why.
- Subscription traps, fake “launch offers”, and countdown timers. Authorised medicines do not need pressure tactics.
- Claims matching injection-level results from a tablet. Foundayo's real trial numbers are good — anything dramatically better than them is fiction.
Who it may suit
Foundayo tends to suit people who want the simplest possible routine: no injections, no fasting window, no fridge storage, easy travel. Eligibility follows the usual weight-management framework — BMI of 30 or above, or 27 or above with a weight-related condition, decided by a prescriber case by case. People chasing the maximum proven effect will currently be steered toward the injections, and people who prefer the established record may prefer the older medicines; Foundayo's long-term real-world profile is, by definition, the shortest. As with every medicine in this class, it works best alongside the food, movement and follow-up support a regulated provider supplies — and stopping treatment usually means weight returns.
Related pages
- The Wegovy pill — the other oral GLP-1, and how its food rules compare; providers at ogovy.co.uk.
- Wegovy injection in the UK — regulated providers at igovy.co.uk.
- Mounjaro in the UK — the strongest authorised injection; prices at monj.co.uk.
- Retatrutide vs Mounjaro vs Wegovy — where the next generation fits.
Cite this page
Johnson N. Yezz — independent UK retatrutide information. Medstack Ltd, 10 September 2026. https://yezz.co.uk/foundayo-uk
Sources
Every factual claim on this page traces to one of these primary sources. We link out so you can check the original.
- 1.dayo.co.uk — list of regulated UK Foundayo providers — verified-provider shortlist for orforglipron in the UK
- 2.GPhC pharmacy register — verify any UK pharmacy yourself
- 3.MHRA products register — confirm the UK licence for orforglipron (Foundayo)
- 4.MHRA — medicines safety alerts — report suspect products via Yellow Card
- 5.NICE — weight-management medicine appraisals and NHS context